Trending News

How Are Family Offices Building Smarter Wealth? Structural Alpha (11 Examples)

DOJ Rule Restricting Sensitive Data Transfers Takes Effect

The Trump Administration’s Diversity, Equity, and Inclusion (DEI) Executive Orders: A Brief Primer

Trump Administration Announces "Reciprocal" Tariffs

What Every Multinational Company Should Know About … The Global and Reciprocal Tariffs Announcement

Blockading the Ports: U.S. Imposes 10% Global Tariff; Higher Reciprocal Tariff Rates by Country

Fifth Circuit Court of Appeals Negates Ruling on Federal Contractor Minimum Wage

New Executive Order Rescinds the $17.75 Per Hour Federal Contractor Minimum Wage

Medicare Telehealth Gets Another Temporary Lifeline – Will Congress Make it Permanent?

BREAKING: District Court Restores Status Quo Ante At NLRB

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
Posted On Thursday, February 13, 2025
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups
Posted On Thursday, February 13, 2025
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
Posted On Thursday, February 13, 2025
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
Posted On Thursday, February 13, 2025
BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)
Posted On Thursday, February 13, 2025
Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit
Posted On Wednesday, February 12, 2025
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Posted On Wednesday, February 12, 2025
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time
Posted On Wednesday, February 12, 2025
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
Posted On Wednesday, February 12, 2025
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Posted On Wednesday, February 12, 2025
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Posted On Wednesday, February 12, 2025
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Posted On Wednesday, February 12, 2025
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Posted On Wednesday, February 12, 2025
Tanke Biosciences Corp Announces Appointment of Vincent Renz as Chief Executive Officer and Member of the Board of Directors
Posted On Wednesday, February 12, 2025
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
Posted On Wednesday, February 12, 2025
ZymoChem Achieves Commercial-Scale Production of Key Biopolymer Ingredient For BAYSE BioSAP
Posted On Wednesday, February 12, 2025
New York Blood Center Enterprises Researchers Identify New Immune Response Mechanisms in Sickle Cell Disease
Posted On Wednesday, February 12, 2025
Bluejay Therapeutics Appoints Mary Cromwell as Senior Vice President and Head of Technical Operations
Posted On Wednesday, February 12, 2025
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Posted On Wednesday, February 12, 2025
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
Posted On Wednesday, February 12, 2025
PharmaTher Provides Update on FDA New Drug Application for Ketamine
Posted On Wednesday, February 12, 2025
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Posted On Wednesday, February 12, 2025
KALA BIO Announces Chief Executive Officer Transition
Posted On Wednesday, February 12, 2025
T-knife Therapeutics to Participate in Two Investor Conferences in March
Posted On Wednesday, February 12, 2025
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Posted On Wednesday, February 12, 2025

Print